Category Archives: Stem Cell Therapy

PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will participate in a panel titled Next Generation Gene Editing at Chardans 6th Annual Genetic Medicines Conference on Monday, October 3, 2022, at 10:30 AM ET.

A live webcast of the event will be available on the Events & Presentations page of Centurys website. A replay of the webcast will be archived on the Company's website for a limited time.

About Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visitwww.centurytx.com.

Century Therapeutics Forward-Looking Statement

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as may, might, will, should, expect, plan, aim, seek, anticipate, could, intend, target, project, contemplate, believe, estimate, predict, forecast, potential or continue or the negative of these terms or other similar expressions. These statements are not guarantees of future performance These risks and uncertainties are described more fully in the Risk Factors section of our most recent filings with the Securities and Exchange Commission and available at http://www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For More Information: Company: Elizabeth Krutoholow investor.relations@centurytx.comInvestors: Melissa Forst/Maghan Meyers century@argotpartners.comMedia: Joshua R. Mansbach century@argotpartners.com

Continued here:
Century Therapeutics to Present at Chardan's 6th Annual - GlobeNewswire

Cell Regeneration Medicine Market Snapshot (2022-2032)

[250 Pages Report] According to Future Market Insights newly releasedCell Regeneration Medicine Marketanalysis report, the global market valuation stands atUS$ 30.3 Bnin 2021 and is expected to be valued atUS$ 34.3 Bnby the end of 2022. The market is expected to rise significantly at a CAGR of14.4%and the global valuation is expected to beUS$ 130.8 Bnby the end of 2032. During the forecasted period (2022-2032), the global market is anticipated to offer an absolute dollar opportunity ofUS$ 96.5 Bn.

The Therapeutics segment is predicted to be the top product segment in the Cell Regeneration Medicine Market with an expected CAGR of16.5%for the period between 2022 and 2032. This is significantly higher from the historical CAGR of14.1%owing to higher adoption of primary cell-based therapies in clinical application and their increased usage in different therapeutic indications.

Furthermore, Cell Regeneration Medicine garners highest revenue through the Oncology segment, which accounts for over a quarter share. The market revenue through Oncology segment is expected to experience the CAGR of13.1%in the therapeutic category as compared to its historical average of11.4%.The category is expected to rise due to high cancer prevalence, increasing investments in cancer research, development of advanced cell therapies and initiatives to reduce cancer burden.

Revenue of Cell Regeneration Medicine Market from 2017 to 2021 Compared to Demand Outlook for 2022 to 2032

As per the publications released by Future Market Insights market research and competitive intelligence provider, on Cell Regeneration Medicine Market, the market is currently valued atUS$ 30.3 Bnin 2021 and is expected to rise at a CAGR of14.4%during the period between 2022 and 2032. This growth has been significantly higher than the historical growth of12.4%.The market is expected to offer an absolute dollar opportunity ofUS$ 96.5 Bnbetween 2022 and 2032. By the end of 2032, the global market for Cell Regeneration Medicine is likely to hit the valuation ofUS$ 130.8 Bn.

Request a Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15084

The market valuation is projected to grow at a significant CAGR of14.4%as compared to historical CAGR of12.4%owing to factors such as introduction of gene therapy, advancements in stem cell and tissue engineering, ongoing funding in R&D by government and commercial entities and continuous regulatory approvals for advanced therapeutic medical products.

What Factors are driving the Growth of Cell Regeneration Medicine Market?

Global Cell Regeneration Medicine Market is likely to be driven by theintroduction of gene therapy,advancements in stems cells and growth intissue engineering. Furthermore, various projects like T-Cell therapy, which comes underthe manufacturing industry of cell therapyregenerative medicinearebeing undertaken by any businesses in cooperationwith other businesses or research institutions. Furthermore, the government regulatory approvals has led to increase in the market growth.

The global pandemic has provided the global players with various chances to bring medicinal solution to fight against SARS-COV-2. Along withvarious initiatives, theongoing investments bygovernment and private sector agencies inR&D has accelerated the industrys advancement. Companies are collaboratingto expand their R&D skills to develop and sell innovative therapies to secure a position in a competitive global market.

Researchers perspectives on Cell Regeneration Medicine have been transformed by technological developments like Nanotechnology,3D bioprintingtechniques and AIin stem cell-based therapeutics. These developments aremakingdermatological grafting operations like persistent burns, bone abnormalities and skin woundsmore efficient. The market is being driven by the rising frequency of chronic medical conditions and genetic abnormalities such as congestive heart failure, myocardial infarction, Parkinsons disease andvarious kinds of bone losses. In addition, the growing elderly populationsuffering from musculoskeletal, oncologicaland cardiological problemsis driving market expansion.

ContactourMarket Research Specialist @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-15084

What Factors are restraining the Growth of Global Cell Regeneration Medicine Market?

The sales of Cell Regeneration Medicine is likely to be affected by the high cost of therapies. This high cost of treatment acts as a barrier in entering the new market. People in emerging economies are unable to finance organ transplantation due to socioeconomic constraints. Organ trafficking is a serious crime that is inprevalencedue to a scarcity of organs.

The developing countries pose to be a potential marketwith rising rates of chronic diseases, hereditary diseases, rising geriatricpopulation and higher demanding regionsfor organs and biomaterials. Butwithlittle awareness of Cell Regeneration Medicine, these potential markets are difficult to capture. The gene correction treatment involves nucleases that have been modified to successfully change the human genome. However, the use of gene correction treatment is limited due to someunintended consequences, such as cell manipulation, which hasimpacted the efficacyofcell formation and proliferation. However, with sufficient capital and financing, R&D is proceeding toward the cost-effective commercialization of such complex medical operations.

Country-wise Analysis

Which Country is the Driving Force for the growth of the Global Cell Regeneration Medicines Market?

In 2021, the United States Accounted for nearly 2/5th share of the global market for Cell Regeneration Medicines. The U.S. market growth is significantly higher from its historical average growth of11.9%. Between 2022 and 2032, the market is estimated to witness an absolute dollar opportunity ofUS$ 36.6 Bn.

The presence of significant playersin the United States, the availability of modern technologiesand increasing financing ofresearch institutes involved in the creation of innovative treatments can all be attributed to this expansion. In addition, the United States has the biggest revenue flow due to a large number of clinical trials, the availability of financing, and various government and private-sector efforts. For example, the US Department of Health and Human Services launched a campaign to place Cell Regeneration Medicine at the forefront of healthcare.

Which Country is expected to grow rapidly in the Global Cell Regeneration Medicines Market?

According to Future Market Insights data, the market in China is anticipated to growat the fastest rate of18.2%between 2022 and 2032. Theprojected CAGR of the U.S. is significantly higher than the historical CAGR of13.7%. In the next ten years, the Chinese market is estimated to offer an absolute dollar opportunityofUS$ 14.8 Bnto reach a valuation ofUS$ 17.8 Bn.

The rising CAGR of the Chinese market for Cell Regeneration Medicines is attributed to the rapid expansion of healthcare infrastructure and research institutes to accelerate stem cell research in a rapidly developing market. With rising government approvals forresearch projects involving human embryonic stem cells,scientists are encouragedto investigate the cellsclinical potential. Additionally, the rising prevalence of cardiovascular and musculoskeletal illnesses is driving this trend. Furthermore, the market is likely to be explored by global players targeting the untapped segments of the market.

Category-wise Insights

Which Product Type is gaining the Utmost Traction in Cell Regeneration Medicine Market?

The Therapeutics segment is the largest revenue generating segment in the Global Cell Regeneration Medicine Market, growing at a CAGR of17.8%during the period between 2022 and 2032.

Despite source diversification, this category is anticipated to maintain its leadership position in the marketplace throughout the projected period. Primary cell-based therapies are the most developed medications available from the medical sector, as they are suitable for use in both clinical applications and approved in different areas. In addition, the stem cell & progenitor cell-based therapies market is predicted to grow significantly over the forecast years, owing to increased investments in stem cell research and regulatory policy revisions.

Which Therapeutic Category is expected to drive the Growth of Global Cell Regeneration Medicines Market?

Oncology therapeutic category is expected to lead the market with the highest share in global market for Cell Regeneration Medicines. It is forecasted to grow at a CAGR of13.1%during the period.

This can be attributable to high cancer prevalence globally and the development of efficient cancer treatment options. Furthermore, huge investments by government organizations and private companies to finance cancer research is aiding the growth.

Competitive Analysis

A number of companies invested in the development of cell regenerative medicine to meet demand for clinical needs without resorting to more-invasive procedures. The market is extremely competitive, and players are making joint efforts for product development.

Some of the prominent Cell Regeneration Medicine manufacturers are AstraZeneca plc, Astellas Pharma, Inc., F. Hoffmann-La Roche Ltd., Integra Lifesciences Corp., Cook Biotech, Inc., Bayer AG, Pfizer, Inc., Merck KGaA, Abbott, Vericel Corp., Novartis AG, GlaxoSmithKline (GSK), Baxter International, Inc., Takara Bio, Inc.

Get in Touch With Our Team For 20% Flat Discount @ https://www.futuremarketinsights.com/request-discount/rep-gb-15084

The recent developments in the Global Cell Regeneration Medicine Market are:

Cell Regeneration Medicine Market Report Scope

Details

Forecast Period

2022-2032

Historical Data

2017-2021

Quantitative Units

In US$ Mn

Key Regions Covered

North America, Latin America, Europe, APAC and MEA

Key Countries Covered

United States, China, Japan, South Korea, U.K., Canada, Brazil, Mexico, Germany, France, Spain, Italy, Russia, India, Australia, South Africa, Saudi Arabia, UAE, Israel

Key Market Segments Covered

Product Type, Therapeutic Category and Region

Market Segments Covered in Cell Regeneration Medicine Market Analysis

By Product Type:

By Therapeutic Category:

By Region:

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:Future Market Insights,Unit No: 1602-006,Jumeirah Bay 2,Plot No: JLT-PH2-X2A,Jumeirah Lakes Towers,Dubai,United Arab EmiratesFor Sales Enquiries:sales@futuremarketinsights.comWebsite:https://www.futuremarketinsights.comLinkedIn|Twitter|Blogs

Read more from the original source:
Cell Regeneration Medicine Market to be valued at US$ 34.3 Bn by the end of 2022 | FMI Research - PharmiWeb.com

A 78-year-old Rockland County cancer survivor may be the oldest-ever recipient of allogenic stem cell treatment. Essie Oates is in remission after her 41-year-old son Oliver donated his bone marrow for a transplant. Typi- cally, a patient over the age of 70 wouldnt be recom- mended for the risky procedure. But Montefiore Einstein Cancer Center Nurse Practitioner Rosma Mathew told the Rockland County Times that Oates was approved for the procedure because she was in such good shape and fighting spirit.

A mother-of-two, Oates, who was raised in South Carolina and has lived in Clarkstown for 45 years, was one of 20,000 diagnosed with acute myeloid leukemia last year. She began her four cycles of stem cell treatment last Feb- ruary, four months after her July diagnosis and several rounds of chemotherapy.

At one point we were doubtful that she would be able to stand this procedure, Mathew told the Rockland County Times. I told her [the things that could happen] so many times, and she was like lets go for it.'

Oates sought out a second opinion after her first doctor would not approve her for the treatment; Dr. Aditi Shastri at New York Presbyterian approved her for the lifesaving procedure after a consultation, telling her that age is just a number.

On September 11, Oates celebrated her 78th birthday with her family, and told the Rockland County Times that her loved ones couldnt believe how good [she] looked.

I just want people to know that you can do it youll be surprised. you have to believe it, she said. Just because the norm is set or something doesnt mean that you cant do it just because someone else said you cant.

The mother-of-two credits her vitality to eating right and exercise. Her active lifestyle includes regular walks around Rockland Lake and across the Tapen Zee Bridge, plenty of outings with her two dogs, and a healthy diet devoid of red meat.

She also credits her recovery to her faith and her Mon- tefiore care team: Its hard to say how nice they are and the positivity they give me.

Read more:
Clarkstown woman beats Leukemia | The Rockland County Times - Rockland County Times

A stem cell is a specific type of cell in the body that has the potential to form many different cell types. So stem cells generally are undifferentiated, and then the kind of cells that they make would become the more mature cells that you're familiar with. So generally, if you think about it, stem cell is the top brick in a big pyramid, and at the base of the pyramid are maybe four different kinds of cells that are derived from that stem cell. And you can see that not only do they mature as they head down the pyramid, but they get greater in number. So a very small number of stem cells can give rise to an enormous number of mature progeny. Now, there are several different kinds of stem cells. There are somatic stem cells. These are the ones that live in the adult organism. And people have stem cells in their bone marrow that give rise to all the different kinds of blood that they have. There are stem cells in the liver that give rise to hepatocytes and secretory cells. There are stem cells in neural tissue that give rise to neurons and astroglial cells and things like that. And muscle has stem cells. And there are many different kinds of stem cells that have been identified in adults. There are also embryonic stem cells, and these are derived from three and a half days in the mouse and about six- to eight-day embryos in people, and these are cells with even more potential than the adult cells, because an embryonic stem cell derived in the proper way can give rise to neural cells, muscle cells, and liver cells. And these are the three different general parts of an organism that happens during its development. So the very important thing to remember about stem cells is they need not only divide and proliferate to make these many, many mature progeny cells, they also need to assure that their own stem cell pool is not reduced. So it's kind of like if you're getting three wishes, your last wish should be for more wishes. So what stem cells do is they have two different kinds of divisions they can make. They can make what's called a symmetric division, where the stem cell divides and both cells stay undifferentiated in stem cells. Or they can make asymmetric division, in which one cell goes on to proliferate and differentiate into the progeny, and the other cell stays a stem cell. So in periods like after a bone marrow transplant, where the stem cell number has to expand, they make many more symmetric than asymmetric divisions. But in the regular time in your bone marrow, the stem cells make mostly asymmetric divisions, which keep the number of stem cells pretty standard.

More:
Stem Cell - Genome.gov

The decision will have widespread implications for the cell and gene therapy (CGT) sector as well as for patient safety, says theInternational Society for Cell & Gene Therapy (ISCT).

The judgement is flawed, according to the industry organization. It said the decision has inserted regulatory uncertainty into the CGT market, creating opportunities for clinics offering purported treatments that are scientifically unproven and potentially dangerous to patients:

The ruling reinforces the imperative market need for informative resources that establish scientific consensus, standards, and best practices, commentedISCT president, Jacques Galipeau.

Late August saw a US federal judge, Jesus G Bernal of the Central District of California, issue a landmark decision siding with the California Stem Cell Treatment Center (CSCTC) and Cell Surgical Network Corporation, in a lawsuit brought by the US Food and Drug Administration (FDA).

The FDA took the legal action against CSCTC in 2018 to assert regulatory authority over stem cell therapies. The agencys position is that taking a patients fat and digesting it with an enzyme to isolate the stem cell fraction creates a biologic drug that requires full FDA approval.

The court rejected this argument.Instead, the judge accepted CSCTCs position that its treatments qualified for an exception from FDA regulations, in part because they were tantamount to surgical procedures.

The court wrote: "The adipose tissue the defendants remove from patients clearly consists of human cells. And whatever is injected back into patients as part of [the] defendants' SVF surgical procedure and expanded MSC surgical procedure certainly contains such cells."

Reacting to the decision, Dr Elliott Lander, co-founder of CSCTC, said the centre appreciated the court's clear and unequivocal ruling, which affirms what we have been saying for 12 years: that our innovative surgical approach to personal cell therapy is safe and legal.

However, Professor Paul Knoepfler, whois based at the UC Davis Department of Cell Biology and Human Anatomy, disagrees. He claims the judge wrongly concluded that stromal vascular fraction (SVF) cells are not changed by the procedure to isolate them.

And the ISCT also believes that scientific inaccuracies in the ruling may have impacted the judges decision.

Its committee on the ethics of cell and gene therapy identified several examples of statements that are problematic and unfounded:

Firstly, they found that the ruling made several statements concerning SVF that are both inaccurate and unsupported by current scientific knowledge. "The ruling mistakenly claims the production of SVF is essentially equivalent to surgery and mischaracterizes SVF as a naturally occurring, circulating, unaltered biological entity that is simply relocated from adipose tissue to other diseased parts of the body by surgical means."

Secondly, the committee argues that the court's assertion that the clinical networks use FDA-authorized devices to produce autologous stem cell-based interventions does not consider that the devices in question may not have been authorized by the FDA, or authorized for other purposes, and have not been designed to produce stem cell therapies.

They also found that the statement that culture-expanded mesenchymal stem cells (MSCs) should not be regulated as drugs conflicts with scientific evidence. "This statement opens the door to unchecked administration of poorly characterized and non-standardized cell preparations with unknown safety and efficacy and may pose significant risks to patients."

Laertis Ikonomou, chair of the ISCT committee on the CGT ethics, said: "ISCT has worked for many years now, alongside the FDA and other regulators across the globe, to ensure all those offering cell and gene, and advanced therapies, operate within established clinical regulatory frameworks to uphold scientific standards and ensure treatments are safe and effective before they reach patients. CGTs currently hold unparalleled potential to treat a vast range of conditions that are underserved needs. However, as one of the most advanced and novel fields of medicine, enhancing patient's own cells, these therapies must operate entirely through a global regulatory framework subject to the most stringent scientific standards."

Read the original:
ISCT: California stem cell ruling is flawed and has inserted regulatory uncertainty into the CGT market - BioPharma-Reporter.com

Chicago, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Stem Cell Therapy Marketis projected to reach USD 558 million by 2027 from USD 257 million in 2022, at a CAGR of 16.8% during the forecast period, according to a new report by MarketsandMarkets. Key drivers of the stem cell therapy market include increase in stem cell research funding, expanding number of clinical trials related to stem cell therapies, and growing number of GMP-certified cell therapy production facilities. However, high costs associated with the development of stem cell therapy along with the ethical concerns related to embryonic stem cells are likely to hamper the market growth to a certain extent.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48

Browse in-depth TOC on "Stem Cell Therapy Market155 Tables 43 Figures 166 Pages

The adipose tissue-derived MSCs segment dominates the cell source market in the stem cell therapy through 2020-2027.

The global stem cell therapy market is segmented into adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources. Adipose-derived stem cell tissues can be obtained easily and also possess a variety of the regenerative properties similar to other mesenchymal stem cells/tissues. These cells are multipotent and are easy to isolate & harvest; these qualities have collectively rendered the adipose tissue-derived MSCs segment highest revenue in 2021.

In 2021, the musculoskeletal disorders ranked first in terms of revenue in the stem cell therapy market.

Based on therapeutic application, the global stem cell therapy market is segmented into musculoskeletal disorders, wounds & injuries, cardiovascular diseases, surgeries, inflammatory & autoimmune diseases, neurological disorders, and other therapeutic applications. In 2021, the musculoskeletal disorders application segment accounted for the largest share of the stem cell therapy market. Increasing market availability of stem cell-based therapeutic products across major markets and the growing patient preference for effective & early treatment strategies are driving the growth of this segment.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=48

The Asia Pacific region is the fastest-growing region of the stem cell therapy market in 2021.

The Asia Pacific region is estimated to grow at the highest CAGR in the stem cell therapy market during the forecast period. Japan and South Korea are the key revenue contributors of the Asia Pacific stem cell therapy market. Favorable government support for product approvals and the presence of major players in these countries are anticipated to drive the regional market growth.

The stem cell therapy market is consolidated in nature with prominent players in the stem cell therapy market include Smith+Nephew (UK), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), CORESTEM (South Korea), Pharmicell Co., Ltd. (South Korea), NuVasive, Inc. (US), RTI Surgical (US), AlloSource (US), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), Holostem Terapie Avanzate Srl (Italy), Orthofix (US), Regrow Biosciences Pvt Ltd. (India), and STEMPEUTICS RESEARCH PVT LTD. (India).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=48

Related Reports:

Stem Cell Manufacturing Market by Product (Consumables, Instrument, HSCs, MSCs, iPSCs, ESCs), Application (Research, Clinical (Autologous, Allogenic), Cell & Tissue Banking), End User (Pharma & Biotech, Hospitals, Tissue Bank) - Global Forecast to 2026

Excerpt from:
Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - GlobeNewswire